P/B
5
uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
$1.6B
Market Cap • 10/2/2026
2012
(14 years)
Founded
2014
(12 years ago)
IPO
NASDAQ
Listing Exchange
Netherlands
Country
Valuation
P/S
87,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
4,7
EPS
—
Market Cap
Market Cap
1,6B
EV
1,4B
EV/Revenue
73,3
EV/EBITDA
-7,4
EV/EBIT
-6,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-34,5%
Total Yield
-34,5%
Payout
0%
Retained Earnings
-1,5B
Profitability
Gross Margin
92,5%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
708,5%
Capex/Revenue
3,6%
Capex/D&A
4,6%
Capex/OCF
-0,4%
SBC/OCF
—
% PPE
2,3%
% Goodwill
2,5%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-48,2%
Leverage
N.D./EBITDA
1,4
Debt/Equity
0%
Current Ratio
10
Quick Ratio
9,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!